AMRX · NASDAQ
Amneal Pharmaceuticals, Inc.
$21.10 +0.72 (+3.53%)
Company overview
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with a focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Exchange
- NASDAQ
- Market cap
- $6.7B
- Employees
- 8,300
- Headquarters
- Bridgewater, NJ
- Website
- amneal.com
- CEO
- Chirag K. Patel
- Listed
- May 7, 2018
- P/E
- 55.69
- Dividend yield
- 0.00%
Company financials
- Revenue
- $3B
- Gross profit
- $1.2B
- Operating income
- $359M
- EBITDA
- $626M
- Net income
- $122M
- EPS
- $0.38
- Total assets
- $3.5B
- Total debt
- $2.7B
- Gross margin
- 38.66%
- Net margin
- 4.02%
- Earnings yield
- 1.80%
Showing FY 2025
AMRX
1D
NASDAQ
O20.45H20.49L19.93C20.38-0.10 (-0.49%)Vol4.93M